BIO
Bio-Rad Laboratories, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP effective tax rate non-GAAP | 22.6% | Q1 2026 | — |
| DDPCR instrument revenue growth | 24% | Q1 2026 call | — |
| free cash flow to non-GAAP net income conversion ratio non-GAAP | 153% | Q1 2026 call | — |
| non-GAAP operating margin non-GAAP | 6.6% | Q1 2026 call | — |
| operational non-GAAP gross margin non-GAAP | 53.1% | Q1 2026 call | — |
| cash from operations | $532M | Full-Year 2025 | — |
| free cash flow | $375M | Full-Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIO
this stock
Bio-Rad Laboratories, Inc.
|
$7.60B | -6.3% | +0.7% | 47.2 | 5.7% |
|
ABT
Abbott Laboratories
|
$165.79B | -23.6% | +5.7% | 26.7 | 1.3% |
|
SYK
Stryker Corp
|
$126.41B | -5.9% | +11.2% | 38.2 | 1.6% |
|
MDT
Medtronic plc
|
$107.31B | -12.0% | +8.4% | 22.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$67.33B | -52.5% | +5.5% | 19.0 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIO | -3.3% | -2.6% | -11.9% | -3.3% | -6.3% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -4.2% | -3.9% | -19.5% | -3.5% | -16.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.